# Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal

> **NCT04390594** · PHASE3 · TERMINATED · sponsor: **Institut Pasteur de Dakar** · enrollment: 59 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Nafamostat Mesilate

## Key facts

- **NCT ID:** NCT04390594
- **Lead sponsor:** Institut Pasteur de Dakar
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-13
- **Primary completion:** 2023-02-08
- **Final completion:** 2023-02-08
- **Target enrollment:** 59 (ACTUAL)
- **Why stopped:** In conclusion, the results of the SEN-CoV Fadj trial to date do not meet the objectives of the clinical trial and the sample size required to meet them is clearly too large to be achieved within a reasonable time.
- **Last updated:** 2024-06-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04390594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04390594, "Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04390594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*